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Abstract
Backg round The r e l a t i on s h i p be tween a i rway
hyperresponsiveness (AHR) and obesity, a low-grade system-
ic inflammatory condition, remains largely unknown. It is
established that AHR to indirect stimuli is associated with
active airway inflammation. The objectives were to
investigate the rate of AHR to mannitol in obese subjects
and its changes 1 year after bariatric surgery (BS).
Methods We enrolled 58 candidates to BS severely obese (33
nonsmokers and 25 smokers) without history of asthma and
20 healthy, nonobese participants and related AHR to func-
tional findings and serum and exhaled biomarkers.
Results Before surgery, AHR was observed in 16 (28 %)
obese with the provocation doses of mannitol to induce a
15 % fall in FEV1 (PD15) of (geometric mean [95 % CI]) 83
(24–145) mg. Compared to control participants, obese partic-
ipants had lower spirometric values and higher serum and
exhaled biomarkers (p<0.05 each). After surgery, AHR was
abolished (p<0.01) in all but four obese subjects.
Conclusions Weight loss induced by BS was the key indepen-
dent factor associated to AHR improvement. AHR to mannitol
is highly prevalent in obesity, and it is largely abolished by BS.
Keywords Abdominal obesity . Airway inflammation .
Bronchial hyperreactivity . Indirect bronchoconstrictor .
Systemic inflammation
Introduction
The concurrence of obesity and bronchial asthma has become
an increasing worldwide major public health problem [1, 2].
Some studies show a clear evidence for a relation of airway
hyperresponsiveness (AHR) to body mass index (BMI) [3].
However, the mechanisms of the relationship between obesity,
AHR, and asthma are not sufficiently established [4, 5], and
the impact of its underlying low-grade chronic systemic in-
flammation on AHR remains unsettled [6]. Obesity is charac-
terized by an increased number of resident macrophages in
adipose tissue that secrete a variety of inflammatory mole-
cules, such as leptin and adiponectin [7, 8]. It is known that
AHR to osmotic challenge agents is associated with the pres-
ence of airway inflammation as they increase airway
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osmolarity and induce the release of inflammatory cells and of
mediators that act on their specific receptors on the airway
smooth muscle causing contraction [9, 10].
Bariatric surgery (BS) is the most efficacious therapeu-
tic strategy to achieve major and sustained weight loss in
morbidly obese subjects [11] and is associated with im-
proved systemic inflammation [12]. There have been very
few studies in obese subjects, mostly in asthmatics, to
assess AHR using methacholine [13] before and after ef-
fective weight loss with discrepant results [14–17]. We
investigated the prevalence of AHR to mannitol in obese
candidates to BS before and 1 year after BS. Part of the




This is a prospective, observational study in 58 morbidly
obese individuals (44 females/14 males; aged 46±12 years)
with BMI ≥40 kg/m2 or ≥35 kg/m2 (in patients with obesity-
related diseases), candidates to BS in our center [18]. This
sample of obese subjects was part of a study with a larger
cohort of severe obese candidates to BS aimed to describe
the systemic inflammome before and after BS [19]. Thirty-
three obese individuals were nonsmokers (<10 pack-years)
and 25 current (≥10 pack-years) or former (≥1 year after com-
plete cessation) smokers (38±26 pack-years). Participants
with cardiovascular and pulmonary (i.e., asthma, chronic
obstructive pulmonary disease, and bronchiectasis) diseases
were excluded. One year after BS, participants were also
evaluated. A control group of 20 healthy nonsmokers (16
females/4 males), with normal weight and lung function,
age-matched (46±7 years) was also recruited. Written in-
formed consent (Protocol 2008/4015) was obtained from
each participant according to the requirements of the
Ethics Committee of the Hospital Clínic, Universitat de
Barcelona.
BS including either Roux-en-Y gastric bypass or sleeve
gastrectomy was carried out according to standard proce-
dures [20]. The selection of the surgical technique was
based on the presence of larger BMI, an estimated opera-
tive risk, or the presence of an enlarged liver [21].
Postoperative weight loss was expressed as a percentage
of the presurgical excess weight (% excess weight
loss=[100×[weight before surgery−weight at the time of
evaluation]/[weight before surgery−weight corresponding
to body mass index=25 kg/m2]) [20]. BS was considered
successful when excess weight loss was >50 % of
presurgical excess weight.
Study Design
The 58 enrolled obese subjects visited the laboratory twice on
two consecutive days, before (median, 5 weeks) and 1 year
after BS (median, 13 months). At day 1, clinical evaluation,
forced spirometry, and static lung volumes using our own pre-
dicted values [22–25] were carried out; at day 2, serum and
exhaled samples were obtained, and the mannitol challenge
was performed in all obese participants. At day 1, serum and
exhaled samples and forced spirometry were determined in all
control individuals; at day 2, eight subjects were challenged to
mannitol alone. Control participants were explored once only.
Mannitol Challenge
Mannitol challenge was carried out using a commercially
available kit (Pharmaxis Ltd, Burnham, UK) [26].
Bronchial challenge to mannitol was performed as previ-
ously reported by our group [27]. Pre-challenge baseline
FEV1 was used to calculate the maximum % fall FEV1
after mannitol. The dose of mannitol that induced a fall of
15 % below baseline (i.e., PD15) was expressed as geo-
metric mean (GM) (GM PD15) in milligrams. AHR to
mannitol was defined as PD15<635 mg. The response-
dose ratio (RDR) was calculated as the % fall FEV1 at
the last dose, divided by the total cumulative dose of
mannitol given (expressed as % fall/mg) in milligrams
administered [26]. The test stopped when 15 % fall
FEV1 was achieved or the cumulative dose of 635 mg
had been administered. Mannitol bronchoprovocation was
completed by control and obese individuals without major
adverse events.
Biomarker Measurements
Serum and exhaled samples were obtained and stored at
−80 °C. Serum concentrations of C-reactive protein (CRP)
were determined using an immunoturbidimetry method
(ADVIAChemistry, Siemens Tarrytown, NY, USA) and those
of leptin using the specific enzyme-linked immunoabsorbent
assay (ELISA) kit (Diagnostic Biochem Canada Inc., Ontario,
Canada). Serum adiponectin, soluble tumor necrosis factor-
receptor 1(sTNF-R1), and interleukin (IL)-8 levels were de-
termined using a specific ELISA (US Biological Salem, MA,
USA; IBL international Hamburg, Germany; and Anogen
Ontario, Canada), respectively. Exhaled breath condensate
samples of IL-8 were determined using an EcoScreen con-
denser (Jaeger, Würzburg, Germany) following current rec-
ommendations [28, 29] and specific ELISA kits (Cayman
Chemical Company, Ann Arbor, MI, USA).
All biomarker measurements were performed in duplicate
and the mean value used for analysis. Biomarker concentra-
tions were below the lower limit of quantification (LLQ) in
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some individuals. To avoid a downward bias of biomarkers, a
nominal level of half of the LLQ value was used in the anal-
ysis in individuals with values below the LLQ [30].
Statistical Analysis
Data were expressed as mean±SD or median (interquartile
range). Comparisons between obese and control individuals
before BS were evaluated using one-way ANOVA with
Bonferroni post hoc analysis (parametric) and Kruskal-
Wallis (nonparametric) test. For comparisons between obese
subjects before and after surgery, paired Student’s for related
samples (parametric) or Wilcoxon (nonparametric) tests for
continuous variables were used. Unpaired Student’s
(parametric) and Mann-Whitney U (nonparametric) tests with
Bonferroni-Holm correction were performed to compare
obese individuals with and without AHR. Chi-square and
McNemar tests for categorical variables and Spearman corre-
lations were used as appropriate. An odds ratio calculated
using generalized estimating equations (GEE) analysis
[31], to account for non-independent evaluations from
the same individuals before and after BS, was deter-
mined to assess the potential relationships of anthropo-
metric data, cigarette smoking, and serum and exhaled
biomarkers with AHR response. Statistical analysis was
performed with specialized computer software (SPSS
20.0, Chicago, IL). Unless otherwise stated, significance
was set at p<0.05.
Results
Baseline Findings (Before Bariatric Surgery)
The most relevant characteristics of obese and control individ-
uals are displayed in Table 1. Obese participants had, com-
pared to control, decreased spirometric values, higher FEV1/
FVC ratios, and higher serum and exhaled biomarkers but
lower adiponectin levels. In obese subjects, comorbidities
were common. Eight obese nonsmokers (14 % of total and
24 % of 33 nonsmokers) (median cumulative dose of inhaled
mannitol, 176 mg [range, 5–629 mg]) and the same number of
obese smokers (8 [14 % of total and 32 % of 25 smokers])
(121 mg [range, 5–475 mg]), respectively, were responsive to
mannitol. Responsive obese nonsmokers had, compared
to responsive smokers, lower mannitol-induced baseline
FEV1 (2.59±0.63 and 3.15±0.65 l) and final FEV1 (1.88±
0.56 and 2.57±0.64 l) values, respectively (p<0.05 each),
without differences in the rates of AHR (chi-square test)
(Table 2). The higher were the exhaled IL-8 levels in obese
individuals, the greater were reactivity (RDR) (Rho, 0.35,
p<0.01) and % fall FEV1 (Rho, 0.32, p<0.05) to man-
nitol. AHR was not documented in any of the eight control
subjects. There were no differences between obese non-
smokers and smokers who completed the study.
The logistic regression model fitted to data for all obese
individuals did not yield interaction (all p values >0.4), with-
out significant associations with anthropometric co-variables
Table 1 Demographic, clinical,
and functional characteristics and
serum and exhaled biomarkers in
control and obese participants
before and after bariatric surgery
Unless otherwise stated, data are
expressed as mean±SD, n (%) or
median (interquartile range)
BMI body mass index, OSA
obstructive sleep apnea, MS
metabol ic syndrome, pred
predicted, BD bronchodilator, FVC
forced vital capacity, FEV1 forced
expiratory volume in the first
second, FRC functional residual
capacity, ERV expiratory reserve
volume, sTNF-R1 soluble tumor
necrosis factor-receptor 1, IL
interleukin
*p<0.001 for comparisons between
control and obese subjects
?before surgery; **p<0.05 for
comparisons between control
?and obese subjects before surgery
Control subjects (n, 20) Obese subjects (n, 58) p value
Before After
Age, years 46±7 46±12 47±12 –
Female, n (%) 16 (80) 44 (76) – –
BMI, kg/m2 22±3 * 45±5 * 30±4 <0.001
Waist circumference, cm 81±11 * 130±11 * 97±11 <0.001
OSA, n (%) – 41 (71) 12 (21) <0.001
MS, n (%) 0 44 (76) 10 (17) <0.001
FVC, % pred 105±12* 90±13* 101±13 <0.001
FEV1, % pred 103±13** 94±15** 102±13 <0.001
FEV1/FVC, % 78±5* 83±5 * 80±5 <0.001
BD response, % 2±3 5±6 2±4 <0.01
FRC, % pred ND 73±14 112±22 <0.001
ERV, % pred ND 39±25 113±32 <0.001
C-reactive protein, mg/l 0.4 (0.1–0.5)* 6.4 (3.7–11.4)* 0.4 (0.2–0.8) <0.001
Leptin, ng/ml 13.6 (5.6–19.7)* 46.3 (38.4–96.9)* 13.6 (6.9–22.1) <0.001
Adiponectin, μg/ml 22.1 (18.1–25.9)* 13.4 (8.7–18.8)* 19.0 (12.0–25.2) <0.001
sTNF-R1, ng/ml 0.4 (0.2–0.5)* 1.4 (1.0–1.9)* 0.9 (0.3–1.3) <0.001
IL-8, pg/ml 2.0 (2.0–3.3) 9.4 (2.0–31.7) 3.4 (1.9–14.2) 0.16
Exhaled IL-8, pg/ml 0.9 (0.4–4.0)** 4.4 (1.5–6.6)** 4.0 (1.1–7.1) 0.62
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or cigarette smoking. The levels of exhaled IL-8 had a mar-
ginal association with AHR (odds ratio [OR], 1.10; 95 % con-
fidence interval [CI], 0.97–1.22; p=0.06) only.
Findings after Bariatric Surgery
Sleeve gastrectomy (SG) was performed in 32 and Roux-en-Y
gastric bypass (RYGBP) in 26 subjects, without differences in
the allocation to the two procedures. The three subjects with
<50 % excess weight loss were nonsmokers, two treated with
SG, and one with RYGB. There was an excess weight loss of
76±17 %, and BS was successful (i.e., >50 % excess weight
loss) in 55 participants (95 %). In obese individuals, clinical
and spirometric findings and all but serum and exhaled IL-8
biomarkers significantly improved or normalized (Table 1).
Two subjects ceased cigarette consumption only.
One year after BS, AHR was abolished in 15 out of the 16
responsive individuals. In addition, three preoperative nonre-
sponsive subjects became now responsive to mannitol. A uni-
variate analysis (McNemar’s test) showed a significant reduc-
tion in AHR in obese individuals after BS (p<0.001).
The results from the models fitted to all pre- and postoper-
ative data failed to detect any significant interaction (all
p values >0.2). The GEE analysis [31] showed that the
period of evaluation before and after BS was the key inde-
pendent factor associated with AHR improvement (OR, 4.7;
95 % CI, 1.4–15.4; p<0.01). Cigarette smoking was not relat-
ed to AHR. Likewise, postoperative changes in exhaled IL-8
and in AHRwere not significant (OR, 1.09; 95 % CI, 1.0–1.2;
p=0.07).
Discussion
This is the first prospective study that comprehensively
assessed AHR to mannitol in morbidly obese, non-asthmatic
adults, including smokers and nonsmokers. Two were the
novel findings in our study. First, preoperative AHR to man-
nitol was abolished after BS in all but one individual and
emerged in three new obese individuals. Second, the degrees
of airway sensitivity (PD15) and reactivity (RDR) to mannitol
were considerably altered in obese participants akin to patients
with currently active asthma [26, 32]. The prevalence of AHR
in obese nonsmokers was high when compared to what has
been previously observed in young normal weighted adults
[33]. Similarly, our results extend and complement previous
studies using direct stimuli in normal weighted individuals
[34, 35], obese adults with and without asthma [5], and over-
weight Chinese families of asthmatic adults [36].
The agents that act indirectly to induceAHR are considered
more specific for identifying the presence of airway inflam-
mation and more consistent with the diagnosis of asthma than
direct stimuli [26]. Numerous hypotheses have been sug-
gested to explain the relationships between obesity, asthma,
and AHR, from dietary lifestyle through mechanisms of
Table 2 Differences in outcomes between obese subjects with and without airway hyperresponsiveness (AHR) to mannitol before and after bariatric
surgery
Before p valuea After p valueb
With AHR Without AHR With AHR Without AHR
Patients, n 16 42 – 4 54 –
Age, years 49±7 46±12 0.29 60±4 46±10 0.009
BMI, kg/m2 46±5 44±5 0.79 27±3 30±4 0.11
Waist, cm 134±9 128±11 0.052 97±11 97±11 0.95
Baseline FEV1, % pred 89±15* 96±15 0.15 117±23** 99±13 0.014
Final FEV1, % pred 70±18* 91±18 <0.001 97±17** 94±14 0.79
% Fall FEV1 21±9 6±4 <0.001 16±1 3±6 <0.001
GM PD15, mg 83 (24–145) >635 NA 224 (156–322) >635 NA
RDR, %/mg 0.11 (0.05–1.88) 0.007 (0.003–0.129) <0.001 0.05 (0.05–0.17) 0.008 (0.003–0.011) <0.001
Exhaled IL-8, pg/ml 6.23 (2.94–12.66) 3.97 (1.26–5.70) 0.99 7.10 (2.58–11.46) 3.90 (1.07–6.51) 0.44
Unless otherwise stated, data are expressed as mean±SD or median (interquartile range); baseline FEV1, FEV1 values measured after inhaling the 0-mg
of mannitol capsule; final FEV1, FEV1 values measured at the end of mannitol test; % fall FEV1, mannitol-induced percentage decrease of FEV1 from
baseline to final values; GM (geometric mean) of PD15, provocation dose of mannitol to cause a 15% fall FEV1; RDR, response-dose ratio (% fall FEV1
divided by cumulative dose given of mannitol). For other abbreviations, see Table 1
*p<0.001 for comparisons between baseline and final FEV1 values before surgery; **p<0.05 for comparisons between baseline and final FEV1 values
after surgery
a p value for comparisons between obese subjects with and without AHR before surgery
b p value for comparisons between obese subjects with and without AHR after surgery
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immunoregulation and inflammation [1, 37, 38]. Responsive
obese nonsmokers had a higher likelihood of bronchial asthma
and might therefore identify patients at high risk of asthma
ear ly before the express ion of symptoms [10] .
Notwithstanding, the mechanisms need to be probed further.
From a clinical viewpoint, the significance of a positive re-
sponse to mannitol is highly suggestive of active bronchial
inflammation.
Before surgery, except for serum IL-8 values, obese indi-
viduals had higher biomarkers and lower adiponectin levels
than control individuals, indicating more active systemic in-
flammation [39]. Serum adiponectin levels are reduced in
obese subjects, and this is thought to induce systemic compli-
cations and augment airway inflammation [7, 19].
There were no differences in the rates of preoperative AHR
between obese nonsmokers and smokers, and cigarette
smoking was not related to AHR. Some smokers without clin-
ical asthma can also have significant airway sensitivity to
mannitol that is lost when smoking is stopped after a few
weeks [40]. While the same mechanism of airway inflamma-
tion in obese nonsmokers could be invoked in smokers, it is
known that smoking also recruits airway macrophages and
neutrophils.
Effective weight loss promoted by BS was successfully
achieved after surgery in the obese population and was
associated to a practical abolition of AHR alone with
lung function improvement, including that of most bio-
markers and considerable reduction in comorbidities.
Moreover, although the current study design did not
preclude the role played by other factors that could
influence postoperative evaluations potentially linked to
changes in AHR, multivariate analysis suggested that
BS was a key determinant of the significant AHR im-
provement observed in the obese cohort. The develop-
ment of postoperative AHR in three new obese individ-
uals (one nonsmoker and two smokers) and its persis-
tence in one smoker suggest that aging and residual
systemic inflammation may have also played an influ-
ential role.
The major strength of our study lies in its comprehensive
design to assess clinical, functional, and biomarker outcomes
in a cohort of asymptomatic, non-asthmatic, morbidly obese
individuals with and without smoking habits, before and after
surgery. There were, however, two shortcomings. First, the
number of obese participants was not high due to the stringent
design, and second, the indirect assessment of AHR in the
current study was not compared with that made by direct
stimuli because it was considered too aggressive in the setting
of our study.
In conclusion, baseline preoperative AHR to mannitol in
this cohort of asymptomatic morbidly obese candidates to BS
is substantially high and associated to systemic inflammation;
obese smokers had a similar rate of AHR but not associated to
systemic inflammation. Our study provides new insights into
the pathophysiology of AHR in obese individuals.
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